Page last updated: 2024-09-03

nifekalant hydrochloride and Cardiomyopathy, Congestive

nifekalant hydrochloride has been researched along with Cardiomyopathy, Congestive in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Chen, Q; Tao, L; Xiao, H1
Bando, K; Okamura, H; Ueda, HI1

Other Studies

2 other study(ies) available for nifekalant hydrochloride and Cardiomyopathy, Congestive

ArticleYear
Long-term nifekalant use in a patient with dilated cardiomyopathy and recurrent ventricular tachycardia.
    The Journal of international medical research, 2022, Volume: 50, Issue:10

    Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Humans; Male; Pyrimidinones; Tachycardia, Ventricular

2022
Crystals in the heart.
    Heart (British Cardiac Society), 2004, Volume: 90, Issue:10

    Topics: Adult; Cardiomyopathy, Dilated; Crystallization; Echocardiography, Transesophageal; Female; Heart Diseases; Humans; Infusions, Intravenous; Potassium Channel Blockers; Pyrimidinones; Thrombosis

2004